Should I buy or sell Inhibrx stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INBX shares. View INBX analyst ratings or view top-rated stocks .

What is Inhibrx's stock price target for 2024?

3 Wall Street research analysts have issued twelve-month price targets for Inhibrx's shares. Their INBX share price targets range from $27.00 to $46.00. On average, they expect the company's share price to reach $36.50 in the next twelve months. This suggests a possible upside of 63.0% from the stock's current price. View analysts price targets for INBX or view top-rated stocks among Wall Street analysts .

How have INBX shares performed in 2023?

Inhibrx's stock was trading at $24.64 on January 1st, 2023. Since then, INBX shares have decreased by 9.1% and is now trading at $22.39. View the best growth stocks for 2023 here .

Are investors shorting Inhibrx?

Inhibrx saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 5,290,000 shares, an increase of 5.4% from the October 31st total of 5,020,000 shares. Based on an average daily trading volume, of 441,300 shares, the days-to-cover ratio is presently 12.0 days. Currently, 15.3% of the shares of the stock are sold short. View Inhibrx's Short Interest .

When is Inhibrx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our INBX earnings forecast .

How were Inhibrx's earnings last quarter?

Inhibrx, Inc. (NASDAQ:INBX) released its earnings results on Thursday, November, 9th. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by $0.09. The company earned $0.12 million during the quarter. Inhibrx had a negative net margin of 42,880.00% and a negative trailing twelve-month return on equity of 424.05%.

What other stocks do shareholders of Inhibrx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD) , Trevena (TRVN) , Vivint Solar (VSLR) , Activision Blizzard (ATVI) , Daqo New Energy (DQ) , Fastly (FSLY) , Innovative Industrial Properties (IIPR) , Lovesac (LOVE) and Micron Technology (MU) .

When did Inhibrx IPO?

(INBX) raised $102 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are Inhibrx's major shareholders?

Inhibrx's stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.99%), FMR LLC (3.48%), Loomis Sayles & Co. L P (2.56%), Eventide Asset Management LLC (0.99%), Northern Trust Corp (0.72%) and Schroder Investment Management Group (0.50%). Insiders that own company stock include Brendan P Eckelman , Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe. View institutional ownership trends .

How do I buy shares of Inhibrx?

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Inhibrx Stock Price, News & Analysis (NASDAQ:INBX)

$22.39

+1.62 (+7.80%)

(As of 12/1/2023 ET)

Compare

Today's Range: $19.86
▼
$22.44
50-Day Range: $14.50
▼
$22.39
52-Week Range: $14.31
▼
$32.71

Volume: 277,479 shs
Average Volume: 400,877 shs
Market Capitalization: $1.06 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.50

Inhibrx MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 63.0% Upside
$36.50 Price Target
Short Interest: Bearish
15.31% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.21
Upright™ Environmental Score
News Sentiment: 0.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.45) to ($4.34) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

453rd out of 954 stocks

Biological Products, Except Diagnostic Industry

75th out of 159 stocks

3.5

Analyst's Opinion

Consensus Rating
Inhibrx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $36.50, Inhibrx has a forecasted upside of 63.0% from its current price of $22.39.
Amount of Analyst Coverage
Inhibrx has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
15.31% of the float of Inhibrx has been sold short.
Short Interest Ratio / Days to Cover
Inhibrx has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.
Change versus previous month
Short interest in Inhibrx has recently increased by 5.38%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Inhibrx does not currently pay a dividend.
Dividend Growth
Inhibrx does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Inhibrx has received a 71.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for deficiency diseases", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Inhibrx is -1.21.

1.9

News and Social Media Coverage

News Sentiment
Inhibrx has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Inhibrx this week, compared to 1 article on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inhibrx insiders have not sold or bought any company stock.
Percentage Held by Insiders
22.20% of the stock of Inhibrx is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
82.46% of the stock of Inhibrx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Inhibrx are expected to grow in the coming year, from ($4.45) to ($4.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Inhibrx is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Inhibrx is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Inhibrx has a P/B Ratio of 8.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Inhibrx Stock (NASDAQ:INBX)

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

INBX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INBX Stock News Headlines

November 10, 2023 | msn.com

Inhibrx posts Q3 results

November 10, 2023 | finanznachrichten.de

Inhibrx, Inc.: Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

December 2, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 9, 2023 | finance.yahoo.com

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

November 4, 2023 | msn.com

Inhibrx reports initial Phase I Ewing sarcoma trial data

November 2, 2023 | finance.yahoo.com

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

September 19, 2023 | finance.yahoo.com

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

August 29, 2023 | marketwatch.com

Inhibrx Shares Rise 15% After Private Placement Financing

December 2, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

August 29, 2023 | finance.yahoo.com

Inhibrx Announces $200 Million Private Placement Financing

August 23, 2023 | markets.businessinsider.com

JMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Know

August 23, 2023 | nasdaq.com

JMP Securities Maintains Inhibrx (INBX) Outperform Recommendation

August 23, 2023 | markets.businessinsider.com

JMP Securities Reaffirms Their Buy Rating on Inhibrx (INBX)

August 17, 2023 | msn.com

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

August 16, 2023 | markets.businessinsider.com

LifeSci Capital Sticks to Their Buy Rating for Inhibrx (INBX)

August 8, 2023 | finance.yahoo.com

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

June 27, 2023 | marketwatch.com

Theft in open court: How a fight over lifesaving drugs led to accusations of brazen industrial espionage

May 30, 2023 | finance.yahoo.com

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 11, 2023 | msn.com

JMP Securities Reiterates Inhibrx (INBX) Market Outperform Recommendation

May 9, 2023 | finanznachrichten.de

Inhibrx Inc.: Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 8, 2023 | finance.yahoo.com

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 8, 2023 | finance.yahoo.com

Inhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue Estimates

May 4, 2023 | msn.com

Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?

May 1, 2023 | nasdaq.com

INBX Makes Bullish Cross Above Critical Moving Average

April 26, 2023 | msn.com

Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients

April 26, 2023 | finance.yahoo.com

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

April 13, 2023 | seekingalpha.com

Inhibrx: Undercovered Company With Good Potential

See More Headlines

Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INBX
CUSIP: N/A
CIK: 1739614
Web: www.inhibrx.com
Phone: 858-795-4220
Fax: N/A
Employees: 132
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $36.50
High Stock Price Target: $46.00
Low Stock Price Target: $27.00
Potential Upside/Downside: +63.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-145,230,000.00
Net Margins: -42,880.00%
Pretax Margin: -42,878.64%
Return on Equity: -424.05%
Return on Assets: -66.76%

Debt

Debt-to-Equity Ratio: 1.59
Current Ratio: 10.16
Quick Ratio: 10.16

Sales & Book Value

Annual Sales: $2.19 million
Price / Sales: 483.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.74 per share
Price / Book: 8.17

Miscellaneous

Outstanding Shares: 47,290,000
Free Float: 36,792,000
Market Cap: $1.06 billion
Optionable: Not Optionable
Beta: 2.72

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Mark Paul Lappe (Age 56)
Founder, Chairman, President & CEO
Comp: $1.02M
Dr. Brendan P. Eckelman Ph.D. (Age 44)
Founder & Chief Scientific Officer
Comp: $704k
Ms. Kelly Devine Deck B.S. (Age 42)
CPA, M.S., Executive VP & CFO
Comp: $531.17k
Mr. Quinn L. Deveraux
Founder
Dr. Ashraf Amanullah (Age 55)
Executive VP & Chief Technical Operations Officer
Ms. Leah Pollema J.D.
VP, Corporate Secretary & General Counsel
Dr. Charbel Helaihel Pharm.D.
Vice President of Marketing & Commercial Planning
Mr. Jeffrey J. Jensen
Executive VP & Chief Clinical Operations Officer
Mr. David Matly M.B.A.
Executive VP and Chief Commercial & Business Development Officer
Dr. Carlos Bais Ph.D.
Executive Vice President of Translational Sciences

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Inhibrx stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INBX shares.
View INBX analyst ratings or view top-rated stocks.
What is Inhibrx's stock price target for 2024?: 3 Wall Street research analysts have issued twelve-month price targets for Inhibrx's shares. Their INBX share price targets range from $27.00 to $46.00. On average, they expect the company's share price to reach $36.50 in the next twelve months. This suggests a possible upside of 63.0% from the stock's current price.
View analysts price targets for INBX or view top-rated stocks among Wall Street analysts.
How have INBX shares performed in 2023?: Inhibrx's stock was trading at $24.64 on January 1st, 2023. Since then, INBX shares have decreased by 9.1% and is now trading at $22.39.
View the best growth stocks for 2023 here.
Are investors shorting Inhibrx?: Inhibrx saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 5,290,000 shares, an increase of 5.4% from the October 31st total of 5,020,000 shares. Based on an average daily trading volume, of 441,300 shares, the days-to-cover ratio is presently 12.0 days. Currently, 15.3% of the shares of the stock are sold short.
View Inhibrx's Short Interest.
When is Inhibrx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our INBX earnings forecast.
How were Inhibrx's earnings last quarter?: Inhibrx, Inc. (NASDAQ:INBX) released its earnings results on Thursday, November, 9th. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by $0.09. The company earned $0.12 million during the quarter. Inhibrx had a negative net margin of 42,880.00% and a negative trailing twelve-month return on equity of 424.05%.

What other stocks do shareholders of Inhibrx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU).
When did Inhibrx IPO?: (INBX) raised $102 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.
Who are Inhibrx's major shareholders?: Inhibrx's stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.99%), FMR LLC (3.48%), Loomis Sayles & Co. L P (2.56%), Eventide Asset Management LLC (0.99%), Northern Trust Corp (0.72%) and Schroder Investment Management Group (0.50%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe.
View institutional ownership trends.
How do I buy shares of Inhibrx?: Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:INBX) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial